Management of Dengue with Low Platelet Count

Assessment and Monitoring

• The World Health Organization recommends monitoring complete blood count (CBC) daily to track platelet levels and hematocrit in patients with dengue fever and thrombocytopenia, especially when there is high risk of shock 1
• Assess for warning signs of progression to severe disease, including high hematocrit with concurrent falling platelet count, and signs of plasma leakage or shock 1

Supportive Management

• The American Society of Tropical Medicine and Hygiene suggests providing supportive care, including administering fever and pain medications as needed, but avoiding NSAIDs, particularly aspirin, due to increased bleeding risk 1
• Manage symptoms with supportive care in outpatient settings for uncomplicated cases 1

Hospitalization Criteria

• Consider hospital admission for patients with warning signs of severe dengue, significant thrombocytopenia with bleeding manifestations, high hematocrit with concurrent falling platelets, or comorbidities that increase risk of complications 1

Complications to Monitor

• Monitor for dengue shock syndrome due to plasma leakage 1

Management of Dengue with Severe Thrombocytopenia

Indications for Platelet Transfusion

• The World Health Organization recommends reserving platelet transfusion for patients with active significant bleeding (beyond petechiae) or high risk of life-threatening bleeding, as evidenced by studies published in Blood 2
• Platelet transfusion should be administered with caution, using pooled platelets while monitoring for transfusion reactions, as suggested by research in Blood 2

Management of Dengue with Thrombocytopenia

Coagulation Monitoring

• The American Society of Hematology recommends monitoring PT ratio (not INR alone) and keeping it <1.5 in coagulopathic patients, as evidenced by a study published in the Journal of Thrombosis and Haemostasis 3
• The International Society on Thrombosis and Haemostasis suggests maintaining fibrinogen levels above 1.5 g/L if coagulopathy develops, based on research published in the Journal of Thrombosis and Haemostasis 3

Management of Dengue Fever with Significant Thrombocytopenia

Blood Product Transfusion Strategy

• The World Health Organization recommends maintaining a platelet count above 50 × 10⁹/L in bleeding patients and above 25 × 10⁹/L in non-bleeding patients only if transfusion is necessary, as stated by the Journal of Thrombosis and Haemostasis 4

Management of Elevated Transaminase in Dengue Hemorrhagic Fever

Laboratory Monitoring Strategy

• The Centers for Disease Control and Prevention recommends monitoring transaminase (AST/ALT) every 2-3 days to assess trends in improvement 5
• The World Health Organization suggests maintaining a fibrinogen level >1.5 g/L, if available, to prevent coagulopathy 5

Management of Coagulopathy and Thrombocytopenia

• The American Society of Hematology recommends platelet transfusion only if there is significant active bleeding with a platelet count <50 × 10⁹/L or a high risk of life-threatening bleeding with a platelet count <25 × 10⁹/L in patients without bleeding 5
• The International Society on Thrombosis and Haemostasis suggests maintaining a platelet count >50 × 10⁹/L in patients with bleeding and >25 × 10⁹/L in patients without bleeding 5

Prognosis

• The Centers for Disease Control and Prevention states that with a rising platelet count on day 5, the patient's prognosis is good, with normalization of laboratory parameters usually occurring by day 11, although transaminase levels may remain elevated for up to 2 months after onset 5